Modified RECIST criteria for assessment of response in malignant pleural mesothelioma-Reference-Cited by-同舟云学术

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Published:2004-02 Issue:2 Volume:15 Page:257-260
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Byrne M.J.,Nowak A.K.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/15/2/257/363667/mdh059.pdf

Reference7 articles.

1. Reporting results of cancer treatment;Miller;Cancer,1981

2. New guidelines to evaluate the response to treatment in solid tumors;Therasse;J Natl Cancer Inst,2000

3. Inadequacy of the RECIST criteria for the evaluation of response in patients with malignant pleural mesothelioma (MPM);van Klaveren;Proc Am Soc Clin Oncol,2002

4. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study;Byrne;J Clin Oncol,1999

5. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma;Nowak;Br J Cancer,2002

Cited by 556 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Convolutional Neural Networks for Segmentation of Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance);Journal of Imaging Informatics in Medicine;2024-09-12

2. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II);European Journal of Surgical Oncology;2024-09

3. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma;Lung Cancer;2024-09

4. Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma;Scientific Reports;2024-07-10

5. Impact of Operation on Disease Progression and Survival of Patients With Pleural Mesothelioma;The Annals of Thoracic Surgery;2024-07